3rd Dec 2020 17:55
PureTech Health PLC - Boston, Massachusetts-based biotherapeutics company - Starts phase 2 trial of LYT-100 in "long" Covid-19 respiratory complications, where symptoms persist long after the initial infection has been fought off. LYT-100 is PureTech's product that is being advanced for the potential treatment of conditions involving inflammation, fibrosis and disorders of lymphatic flow. PureTech's global, randomized, double-blind, placebo-controlled phase 2 trial is designed to evaluate the efficacy, safety and tolerability of LYT-100 in adults with post-acute Covid-19 respiratory complications. The primary endpoint of the trial will be six-minute walk test distance. The study has initiated in both the US and Europe, and results are expected in the second half of 2021, it adds.
Current stock price: 305.00 pence
Year-to-date change: down 4.7%
By Arvind Bhunjun; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
PureTech